Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

News & Events

HCRN CEO Brian Stemme Featured on Purdue Pathfinder Podcast

Brian Stemme, Hoosier Cancer Research Network’s (HCRN) chief executive officer, was recently featured on Pathfinder, a Purdue Life Sciences podcast with Dr. Thomas G. Sors from Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D). Stemme shared insights on his career journey, why Indiana is a top spot for life sciences and HCRN’s impactful work.

In their discussion, they delved into Stemme’s career prior to HCRN, highlighting his role as senior vice president at BioCrossroads, manager at Eli Lilly and the part he played as co-founder of AgriNovus.

“I was honored to be featured on the Purdue Pathfinder podcast. Tommy Sors is an advocate for educating and connecting local professionals and students with life sciences opportunities,” he said. Stemme and Dr. Sor’s conversation then shifted to Indiana’s thriving life sciences ecosystem and the part that HCRN plays within it. Stemme emphasized the breadth of assets that Indiana has, in life sciences research and development, manufacturing and product distribution.

Stemme explained that HCRN is a connector, supporter, and ally of academic medical institutions. He stated, “HCRN fills an important need in the clinical research ecosystem and provides significant value to researchers in our network.”

When asked about the significance of opportunities for HCRN to increase awareness and recognition, he said, “To ensure that key stakeholder groups (potential employees, university stakeholders and local businesses) understand our work, we need to actively seek opportunities to tell our story – one I know HCRN employees are really proud of.”

Listen to the full episode: PATHFINDER – Brian Stemme, CEO of Hoosier Cancer Research Network, Inc., (HCRN)

Former HCRN leader, Dr. Robin Zon, appointed ASCO president

Hoosier Cancer Research Network congratulates Dr. Robin Zon on assuming her new role as president of the American Society of Clinical Oncology. Dr. Zon served as HCRN’s vice chair from 2006-2009, and as chief community officer from 2009-2010.  

Read More

Belief-driven workforce: Insights from HCRN’s Brian Stemme

Chief Executive Officer of Hoosier Cancer Research Network, Brian Stemme, authored an article on Inside Indiana Business titled, “Belief-driven employees seek organizations that make a difference,” published May 24, 2024.  

Read More

HCRN’s Presence at ASCO 2024

Hoosier Cancer Research Network (HCRN) is set to participate in the American Society of Clinical Oncology® (ASCO) 2024 Annual Meeting in Chicago from May 31 to June 4. During the event, five HCRN studies will be presented, working group meetings will take place, and HCRN will host a joint reception with the Big Ten Cancer Research Consortium. The HCRN team will also be present in the exhibit hall at booth #37113.

Read More

HCRN seeks biorepository technician

Hoosier Cancer Research Network (HCRN) is currently seeking a full-time biorepository technician. Two years of lab experience preferred.

HCRN is an independent nonprofit contract research organization based in Indianapolis, Ind., that specializes in early phase, multi-center, investigator-initiated oncology clinical trials. Our studies are conducted through a nationwide network of more than 100 academic and community sites.

Read More

Reps for Research Update

Hoosier Cancer Research Network is excited to share that Reps for Research 2024 has raised $3,060, bringing our 7-year cumulative total to more than $26,000.

Reps for Research took place on March 3, 2024, as fundraiser for Hoosier Cancer Research Network (HCRN) led by Christopher A. Fausel, chairman of HCRN’s board of directors and oncology precision genomics pharmacist at the IU Simon Comprehensive Cancer Center. The event included Fausel’s participation in the Arnold Sports Festival Pump & Run 5K in Columbus, Ohio.

Read More

HCRN seeks protocol and correlative development manager

Hoosier Cancer Research Network (HCRN) is currently seeking a full-time protocol and correlative development manager. Oncology clinical trial knowledge and/or experience is required. Experience as a clinical study trial coordinator, CRO project manager, correlative management or oncology research nurse is preferred.

HCRN is an independent nonprofit contract research organization based in Indianapolis, Ind., that specializes in early phase, multi-center, investigator-initiated oncology clinical trials. Our studies are conducted through a nationwide network of more than 100 academic and community sites. Read More

HCRN lymphoma working group co-chairs driven by science and mentorship

Co-chairs of the HCRN Lymphoma Working Group, Jonathan B. Cohen, MD, Natalie Galanina, MD, and Natalie Grover, MD, were driven by science and the influence of strong mentors early in their careers. It’s also why lymphoma is a focus of their work as they see great opportunities to make an impact through the WG collaboration.

Dr. Cohen is associate professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, and co-director of the Lymphoma Program at Winship Cancer Institute of Emory University; Dr. Galanina, is associate professor of medicine at the University of Pittsburgh Medical Center; and Dr. Grover is associate professor of medicine, clinical director, Cellular Therapy Program, and leader, Cell Therapy POD at the University of North Carolina School of Medicine. Read More

Reps for Research is back

Hoosier Cancer Research Network is excited to announce that Reps for Research is returning March 3, 2024, after a three-year hiatus.

Reps for Research is a fundraiser for Hoosier Cancer Research Network (HCRN) that is led by Christopher A. Fausel, chairman of HCRN’s board of directors and oncology precision genomics pharmacist at the IU Simon Comprehensive Cancer Center. The event includes Fausel’s participation in the Arnold Sports Festival Pump & Run 5K in Columbus, Ohio.

Fausel invites pledges in support of HCRN for every bench press “rep” he completes during the event, with a maximum of 30 “reps.” Donations received will directly support investigator-initiated research, which is central to HCRN’s vision and mission.

Read More

HCRN study in Merkel cell now enrolling

A new Hoosier Cancer Research Network clinical trial studying Merkel cell carcinoma is currently recruiting subjects.

The trial, A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN-MCC20-443; iPRRT Study), is led by Pashtoon Kasi, MD, MS, of Cornell University and is currently recruiting subjects at New York-Presbyterian/Weill Cornell Medical Center.

Read More

HCRN sarcoma co-chairs united in vision and goals for new working group

2023 marked the establishment of a new Sarcoma Clinical Trial Working Group for HCRN. The group brings together some of the sharpest minds in cancer research who are focused on one of the rarest types of cancer.

The working group is led by (pictured from left) Atrayee Basu-Mallick, MD, interim director, Solid Tumor Division, and associate professor at Thomas Jefferson University; Mark Agulnik, MD, professor and section chief of sarcoma medical oncology in the Department of Medical Oncology & Therapeutics Research at City of Hope; and Kristen Ganjoo, MD, professor of medicine at Stanford University School of Medicine and the director of Stanford Sarcoma Program. The co-chairs are united in their goal of connecting sarcoma researchers who share a common purpose of finding more treatments for this challenging cancer.

Read More

HCRN GI14-198 published findings in European Journal of Cancer

Researchers participating in HCRN GI14-198, recently reported findings in the European Journal of Cancer. The study was a phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients.

Read More

HCRN study featured in trials in progress at SNO Annual Meeting

Researchers participating HCRN BRE21-516, also known as BRIDGET, had their work featured as a Trials in Progress abstract at the Society for NeuroOncology Annual Summit. The study focuses on secondary brain metastases prevention after isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib.

Read More

HCRN lung cancer study published in The Oncologist

HCRN LUN13-175 recently had its findings published in The Oncologist. Led by Nisha Mohindra, MD of Northwestern, this trial was a phase I/II trial of carboplatin, Nab-paclitaxel, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).

Read More

ASCO honors Patrick J. Loehrer, MD, with Humanitarian Award

During the 2023 ASCO Annual Meeting, Patrick J. Loehrer, MD, FACP, FASCO, received the ASCO Humanitarian Award in recognition of his work personifying ASCO’s mission and values as well as providing service and leadership both at home and abroad.

Read More

HCRN investigators present three abstracts during ASCO 2023

Three Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.

Read More

Meet Hoosier Cancer Research Network at ASCO 2023 Annual Meeting

Hoosier Cancer Research Network (HCRN) will have an exhibitors booth at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Visit Booth #28115 to talk with our highly qualified staff about our 35 years of experience managing oncology/hematology multi-center clinical trials.

Read More

HCRN Urothelial Cancer Study presents findings at 2023 ASCO GU Cancers Symposium

Hoosier Cancer Research Network urothelial cancer study was highlighted during the 2023 ASCO Genitourinary Cancers Symposium in San Francisco. In a poster and rapid abstract session presentation during the 2023 ASCO Genitourinary Cancers Symposium. Jason Brown, MD, PhD, of University Hospitals Seidman Cancer Center presented the results of HCRN GU14-188, a Phase Ib/II trial of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.

Read More

HCRN bladder cancer study published in European Urology

Researchers participating in the study known as ADAPT-BLADDER, or HCRN GU16-243, recently reported preliminary findings in the journal European Urology. The study evaluated the safety and preliminary efficacy of anti-PD-L1 directed therapy with durvalumab (cohort 1), durvalumab plus Bacillus Calmette-Guerin (BCG) (cohort 2) and durvalumab plus external beam radiation therapy (EBRT) (cohort 3).

Read More

HCRN Remembers Alesha Arnold, RN: A dedicated board member committed to finding a cure

It is with heavy hearts we share the passing of Hoosier Cancer Research Network Board Member Alesha Arnold, RN.

Alesha was a breast oncology research nurse at the IU School of Medicine and supported the Clinical Trials Office at the IU Melvin and Bren Simon Cancer Center. Alesha worked with Clarian Health from 1997 to 2003 and served as a Clinical Research Nurse in gynecological cancer and breast cancer from 2008 to 2023. Alesha was also a patient at the IU Melvin and Bren Simon Cancer Center from 2019 to 2023.

Read More
More News & Events →